Biomerica Inc. | Income Statement

Fiscal year is June-May. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
5,120.50
4,962.40
5,139.80
5,791.70
5,564.20
Cost of Goods Sold (COGS) incl. D&A
3,451.20
3,420.60
3,615.80
3,769.90
3,809.80
Gross Income
1,669.20
1,541.80
1,524.00
2,021.80
1,754.40
SG&A Expense
2,115.80
2,212.40
2,351.00
2,976.40
3,236.20
EBIT
446.60
670.60
827.00
954.60
1,481.80
Non Operating Income/Expense
3.10
2.30
6.80
0.30
0.00
Interest Expense
0.10
-
-
-
-
Pretax Income
426.40
646.40
796.00
908.60
1,434.00
Income Tax
210.80
315.00
703.80
-
31.80
Consolidated Net Income
215.70
331.40
1,499.80
908.60
1,465.80
Net Income
215.70
331.40
1,499.80
908.60
1,465.80
Net Income After Extraordinaries
215.70
331.40
1,499.80
908.60
1,465.80
Net Income Available to Common
215.70
331.40
1,499.80
908.60
1,465.80
EPS (Basic)
0.03
0.04
0.20
0.11
0.17
Basic Shares Outstanding
7,370.80
7,552.30
7,626.10
8,329.80
8,570.00
EPS (Diluted)
0.03
0.04
0.20
0.11
0.17
Diluted Shares Outstanding
7,370.80
7,552.30
7,626.10
8,329.80
8,570.00
EBITDA
239.60
417.30
594.50
735.40
1,295.20
Non-Operating Interest Income
17.20
21.90
24.10
46.40
47.80

About Biomerica

View Profile
Address
17571 Von Karman Avenue
Irvine California 92614
United States
Employees -
Website http://www.biomerica.com
Updated 07/08/2019
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign.